Clinical trial · Observational
Evaluation of the Metastasis and Recurrence of Prostate Cancer
Evaluation of the Metastasis and Recurrence of Prostate Cancer With 18F-PSMA PET/CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and MRI) and molecular imaging methods (11C-choline PET/CT),we hope to find the advantages of 18F-PSMA PET/CT in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer (Diagnosis) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
| Prostate Cancer Stage | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Patients with initial diagnosis of PCa
- description
- 1. T2 stage: PSA\>20ng/ml, Gleason Score \>= 8; 2. T3 or T4 stage; 3. The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity.
- label
- Patients with biochemical recurrent PCa
- description
- 1. After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera; 2. After the radiotherapy: the lowest PSA is up to 2 ng/ml.
- label
- Patients with CRPC
- description
- 1. The serum testosterone is in the castration level (\< 50 ng/dL or \< 1.7 nmol/L); 2. The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA \> 2ng/mL(the interval is one week); 3. The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks; 4. Despite the continued standard androgen deprivation therapy, the PSA is still progressing.
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: 1. Patients with initial diagnosis of prostate cancer; 1）T2 stage: PSA\>20ng/ml, Gleason Score \>= 8; 2）T3 or T4 stage; 3）The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity. 2. Patients with biochemical recurrent prostate cancer; 1）After the RRP surgery, the serum PSA was over 0.2 ng/ml in two consecutive sera; 2）After the radiotherapy: the lowest PSA is up to 2 ng/ml. 3. Patients with CRPC. 1）The serum testosterone is in the castration level (\< 50 ng/dL or \< 1.7 nmol/L); 2）The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA \> 2ng/mL(the interval is one week); 3）The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks; 4）Despite the continued standard androgen deprivation therapy, the PSA is still progressing. Exclusion Criteria: 1. Patients who are unwilling to participate in the study or unwilling to sign the informed consent forms; 2. Patients who are critically ill, suffering from mental illness and cannot cooperate with the examination; 3. There are electronic implants, such as pacemakers and insulin pumps in the body, and magnetic metal foreign objects in the spot.
References
Publications (0)
Data not yet available